Prospective Trial of IVL for Calcified Carotid Lesions(CREATE Trial)(Extended Follow-Up)

Last updated: May 13, 2025
Sponsor: Shanghai Bluesail Boyuan Medical Technology Co., Ltd.
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carotid Artery Disease

Treatment

N/A

Clinical Study ID

NCT06936189
LFBY-202502
  • Ages 18-80
  • All Genders

Study Summary

Purpose: To assess the long-term safety and efficacy of the intravascular lithotripsy system for pre-treatment of calcified carotid artery stenosis.

Design: Prospective, multicenter, single-arm study with an extended follow-up period.

Sample Size: 204 participants (based on the final number of cases enrolled in the registration trial).

Endpoints:

Primary: Surgical success rate (residual stenosis <30% after stenting). Secondary: Target lesion re-narrowing rate, target lesion revascularization rate, MAE rate, ipsilateral stroke rate, and MACCE rate at 3 and 6 months postoperatively.

Follow-Up: Participants will be followed up at 3 months ±15 days and 6 months ±30 days postoperatively.

Inclusion criteria:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Ethics and Consent: The trial will be conducted in accordance with the Helsinki Declaration and Chinese regulations. Informed consent will be obtained from all participants or their legal guardians.

Sponsor: Shanghai Lanfan Boyuan Medical Technology Co., Ltd. Principal Investigator: Professor Huo Xiaochuan, Beijing Anzhen Hospital.

Eligibility Criteria

Inclusion

Inclusion criteria:

All patients participating in this extended follow-up period are sourced from the registered clinical trial.

Exclusion

Exclusion criteria:

none

Study Design

Total Participants: 204
Study Start date:
May 12, 2025
Estimated Completion Date:
December 30, 2027

Study Description

This clinical trial evaluates the safety and long-term efficacy of a disposable neurovascular intravascular lithotripsy (IVL) catheter and intravascular lithotripsy treatment device for pre-treatment of calcified lesions in the extracranial segment of the carotid artery. The study is designed as a prospective, multicenter, single-arm trial （extended follow-up period）.

All patients participating in this extended follow-up period are sourced from the registered clinical trial.（The registered clinical trial:Participants aged 18-80 years with symptomatic (≥50%) or asymptomatic (≥70%) calcified carotid artery stenosis confirmed by CT angiography (CTA) and digital subtraction angiography (DSA) are eligible. Patients who have failed conventional balloon dilation and are planned for carotid artery stenting (CAS) will be included.）

  • Endpoints:

    • Primary Endpoint: Surgical success rate defined as residual stenosis <30% after stenting.

    • Secondary Endpoints: Target lesion re-narrowing rate, target lesion revascularization rate, MAE (major adverse events) rate, ipsilateral stroke rate, and MACCE (major adverse cardiovascular and cerebrovascular events) rate at 3 and 6 months postoperatively.

  • Ethical Considerations:

Informed consent will be obtained from all participants or their legal guardians. The study will be conducted in accordance with the Helsinki Declaration and local regulatory requirements.

Connect with a study center

  • Beijing Anzhen Hospital

    Beijing,
    China

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.